You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 3, March 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology, Other
 •Surgical Oncology
 •Hepatobiliary Surgery
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Effectiveness of Radiofrequency Ablation for Hepatocellular Carcinomas Larger Than 3 cm in Diameter

Ronnie T. P. Poon, FRCS(Edin); Kelvin K. C. Ng, FRCSEd(Gen); Chi-Ming Lam, FRCS(Edin); Victor Ai, FRCR; Jimmy Yuen, FRCR; Sheung-Tat Fan, MD, PhD, FRCS(Edin& Glasg)

Arch Surg. 2004;139:281-287.

Hypothesis  Radiofrequency ablation is a safe and effective treatment for hepatocellular carcinomas 3.1 to 8.0 cm in diameter.

Design  Case series with prospective data collection.

Setting  Tertiary referral center.

Patients  Eighty-six patients with hepatocellular carcinoma treated with radiofrequency ablation from May 1, 2001, to December 31, 2002, were placed into categories of those with tumors 3 cm or smaller (group 1, n = 51) and those with tumors 3.1 to 8.0 cm (group 2, n = 35) in diameter.

Interventions  Radiofrequency ablation was performed with a single or cluster cool-tip electrode. The choice of treatment route was based on tumor size and position.

Main Outcome Measures  Complication, treatment mortality, and complete ablation rates.

Results  Radiofrequency ablation was performed percutaneously in 26 patients in group 1 and 9 patients in group 2, with laparoscopy in 2 patients in group 1 and 1 patient in group 2, and with open operation in 23 patients in group 1 and 25 patients in group 2. The complication rates were 12% and 17% in group 1 and group 2, respectively (P = .48); treatment mortality rates were 0% and 3%, respectively (P = .41). Complete ablation rates after a single session of ablation assessed by means of computed tomography 1 month after treatment were 94% and 91% in group 1 and group 2, respectively (P = .68).

Conclusion  Radiofrequency ablation is a safe and effective treatment for patients with hepatocellular carcinomas 3.1 to 8.0 cm in diameter.


From the Centre for the Study of Liver Disease and Departments of Surgery (Drs Poon, Ng, Lam, and Fan) and Radiology (Drs Ai and Yuen), University of Hong Kong Medical Centre, Queen Mary Hospital, Pokfulam, Hong Kong, People's Republic of China.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incomplete Ablation After Radiofrequency Ablation of Hepatocellular Carcinoma: Analysis of Risk Factors and Prognostic Factors
Lam et al.
Ann. Surg. Oncol. 2008;15:782-790.
ABSTRACT | FULL TEXT  

Comparison of Percutaneous and Surgical Approaches for Radiofrequency Ablation of Small and Medium Hepatocellular Carcinoma
Khan et al.
Arch Surg 2007;142:1136-1143.
ABSTRACT | FULL TEXT  

Comparable Survival in Patients With Unresectable Hepatocellular Carcinoma Treated by Radiofrequency Ablation or Transarterial Chemoembolization
Chok et al.
Arch Surg 2006;141:1231-1236.
ABSTRACT | FULL TEXT  

Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with Cirrhosis
Raut et al.
Ann. Surg. Oncol. 2005;12:616-628.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.